Spike Protein News and Research

RSS

T-cell immunity remains effective against SARS-CoV-2 Omicron subvariants

Omicron subvariants effectively escape B-cell immune responses by modifying neutralizing antibody epitopes.

21 Dec 2022

MHRA authorizes the COVID-19 vaccine developed by Sanofi

VidPrevtyn Beta, the COVID-19 vaccine developed by Sanofi, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

21 Dec 2022

COVID-19 epidemiology can be estimated using blood donation samples

An article published in the journal eLife reports a study in which researchers concluded that the proportion of the population previously infected by SARS-CoV-2 (infection-induced seroprevalence) can be estimated using blood donation samples.

20 Dec 2022

SARS-CoV-2 structural proteins trigger periodontal fibrosis

Researchers examined the pathological impacts of the structural components of SARS-CoV-2 on human periodontal cells and tissue to understand the association between coronavirus disease 2019 (COVID-19) and deteriorating oral health.

20 Dec 2022

Seroprevalence measurements reveal a higher incidence of asymptomatic SARS-CoV-2 infections among residents of three federal German states

Researchers measured the seroprevalence against SARS-CoV-2 in blood donors from the states of Hesse, Lower Saxony, and North Rhine-Westphalia in Germany to determine the incidence of undetected asymptomatic SARS-CoV-2 infections.

20 Dec 2022

Researchers generate a remodeled live-attenuated measles vaccine capable of driving nAb responses against SARS-CoV-2 spike protein

Researchers developed a measles virus (MeV)-vectored vaccine capable of inducing high neutralizing antibody (nAb) responses against SARS-CoV-2.

20 Dec 2022

What is the impact of cholesterol on SARS-CoV-2 Spike protein-mediated membrane fusion?

Researchers assessed the impact of ceramide (CER) and cholesterol (CHOL) on membrane fusion mediated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

20 Dec 2022

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Researchers described four novel monoclonal antibodies with potent and broad neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the current globally dominant Omicron BA.4/BA.5.

20 Dec 2022

Milk antibodies against SARS-CoV-2 after booster vaccination and breakthrough infection

Researchers longitudinally evaluated the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in lactating individuals.

19 Dec 2022

Rise and waning of SARS-CoV-2 antibody responses induced by mRNA vaccine booster in a healthcare worker population

Researchers reported the waning of antibodies against SARS-CoV-2 in the six months following a booster dose of the mRNA COVID-19 vaccine.

19 Dec 2022

Safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222

Researchers evaluated the immunogenicity and safety of the COVID-19 bivalent mRNA vaccine mRNA-1273.222 and tested the neutralizing ability of the two bivalent vaccines — mRNA-1273.222 and mRNA-1273.214 — against the newly emergent Omicron subvariants.

19 Dec 2022

An assessment of T cell and antibody immunity against SARS-CoV-2 VOCs and the effect of booster shots

A new study in the journal Vaccines aimed to analyze the long-term kinetics of SARS-CoV-2 specific T cell and humoral responses following primary and booster vaccinations in previously infected individuals.

18 Dec 2022

Shielding measures conferred protection to pregnant individuals in early COVID-19 pandemic

Individuals who were already pregnant at the beginning of the COVID-19 pandemic had a 50 percent lower exposure to SARS-CoV-2 compared with those who became pregnant after the pandemic began and the general population, according to a new model created by Weill Cornell Medicine, NewYork-Presbyterian and University of Oxford investigators.

16 Dec 2022

Study finds anti-S binding antibody levels are a valid correlate of protection against Omicron BA.1/BA.2 infections

Researchers used serological measurements from a longitudinal cohort to evaluate the use of binding antibodies against the SARS-CoV-2 spike protein receptor binding domain as correlates of protection against the immune evasive Omicron subvariants BA.1 and BA.2.

16 Dec 2022

Scientists identify a novel epitope at the SARS-CoV-2 spike furin cleavage site

Scientists identify an immunogenic epitope at the furin cleavage site of the SARS-CoV-2 spike protein.

15 Dec 2022

Research reveals that a viral toxin may contribute to the severity of COVID-19

Researchers determine whether the SARS-CoV-2 spike protein influences endothelial and epithelial barrier dysfunction and vascular leakage.

14 Dec 2022

What are the risk factors associated with symptomatic SARS-CoV-2 and rhinovirus infection in King County, Washington, from June 2020 to July 2022?

Researchers evaluated the change in symptoms and risk factors associated with positive SARS-CoV-2 tests during the COVID-19 pandemic and compared it to those associated with positive tests of other respiratory viruses among residents of King County, Washington, in the United States.

14 Dec 2022

Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs

Researchers measured the antibodies against SARS-CoV-2 from nasal fluid, saliva, and plasma to compare the antibody levels between blood and mucosal fluids.

14 Dec 2022

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Researchers compare the contribution of antibodies against the SARS-CoV-2 receptor binding domain in vaccinated and naturally infected adults and children.

12 Dec 2022

XBB Omicron variant evades vaccine-induced immunity

A new study published in The Lancet Microbe examines the immune evasion characteristics of the Omicron XBB subvariant.

12 Dec 2022

Spike Protein News and Research

T-cell immunity remains effective against SARS-CoV-2 Omicron subvariants

MHRA authorizes the COVID-19 vaccine developed by Sanofi

COVID-19 epidemiology can be estimated using blood donation samples

SARS-CoV-2 structural proteins trigger periodontal fibrosis

Seroprevalence measurements reveal a higher incidence of asymptomatic SARS-CoV-2 infections among residents of three federal German states

Researchers generate a remodeled live-attenuated measles vaccine capable of driving nAb responses against SARS-CoV-2 spike protein

What is the impact of cholesterol on SARS-CoV-2 Spike protein-mediated membrane fusion?

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Milk antibodies against SARS-CoV-2 after booster vaccination and breakthrough infection

Rise and waning of SARS-CoV-2 antibody responses induced by mRNA vaccine booster in a healthcare worker population

Safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222

An assessment of T cell and antibody immunity against SARS-CoV-2 VOCs and the effect of booster shots

Shielding measures conferred protection to pregnant individuals in early COVID-19 pandemic

Study finds anti-S binding antibody levels are a valid correlate of protection against Omicron BA.1/BA.2 infections

Scientists identify a novel epitope at the SARS-CoV-2 spike furin cleavage site

Research reveals that a viral toxin may contribute to the severity of COVID-19

What are the risk factors associated with symptomatic SARS-CoV-2 and rhinovirus infection in King County, Washington, from June 2020 to July 2022?

Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

XBB Omicron variant evades vaccine-induced immunity

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News